A biotechnology company developing treatments for infectious diseases has signed a long-term lease for approximately 33,000 square feet in downtown New Haven, more than tripling its headquarters space.
Invivyd will occupy space at 205 Church St., near its current 9,000-square-foot headquarters at 209 Church St. The company was previously based in Waltham, Massachusetts, where it still has a research and development lab.
The new lease includes 17,322 square feet on the ground floor, 12,563 square feet on the mezzanine and 2,750 square feet in the basement, according to commercial real estate firm Savills, which represented Invivyd.
“This expansion gives us the space to continue working to advance programs designed to protect people from serious infectious diseases,” said Chief Financial Officer William Duke Jr.
The deal follows Invivyd’s appointment of board Chairman Marc Elia as CEO, effective Aug. 30.
Invivyd develops laboratory-made antibodies to protect people from infectious diseases. Its existing drug, Pemgarda, is authorized for emergency use to prevent COVID-19 in certain people with weakened immune systems. The company is also testing a successor drug, VYD2311, in late-stage clinical trials.
Savills Vice Chairman Craig Lemle and Managing Director Chris Gorczyca represented Invivyd in the lease. CBRE represented the landlord, Cooper Church LLC, which is controlled by New York real estate investor David Kuperberg, according to state business records.
